[Influence of compound biejia ruangan prescription on extracelluar matrix in bleomycin induced pulmonary fibrosis rats].
OBJECTIVE
To study the influence of compound Biejia Ruangan Prescription (CBRP) on extracelluar matrix in bleomycin induced pulmonary fibrosis rats.


METHODS
54 male Sprague-Dawley rats were randomly divided into 6 groups (9 rats in each group). Rats in the model control group, positive medicine group, and high, moderate and low CBRP groups were injected with bleomycin A5 by trachea, and rats in sham-model control group with same volume normal saline. 29 days after the injection, CBRP solution of different dosages (1.4 g x kg(-1), 0.7 g x kg(-1), 0.35 g x kg(-1)) was respectively given to rats in the high, moderate and low CBRP group by gavage, while equal volume of normal saline was given to those in the sham-model control group and model control group, and an equal volume of prednisone (0.56 mg x kg(-1)) was given to those in positive medicine control group. On the 80th day, the levels of III-collagen, IV-collagen, laminin and hyaluronic acid in the serum were determined, the determination of hydroxyproline in lung homogenates was analyzed, and the right lung was incised to make pathological sections which were stained with Hematoxylin-Eosin (HE) and Masson staining for pathological diagnosis.


RESULTS
CBRP could decrease the levels of III-collagen, IV-collagen, laminin and hyaluronic acid in the serum.


CONCLUSIONS
CBRP may play its therapeutic role by leveling down the content of extracellular matrix in rats with pulmonary fibrosis induced by Bleomycin A5.
Zhang
Dong-wei
DW
Laboratory of Cell and Biochemistry of Beijing University of Chinese Medicine, Beijing 100029, China.
Wang
Ji-feng
JF
Niu
Jian-zhao
JZ
Yang
Mei-juan
MJ
Wang
Ling-qiao
LQ
Jin
Huan
H
Liu
Lian-qi
LQ
Gao
Bao-hua
BH
D000818:Animals; D001761:Bleomycin / Q000031:analogs & derivatives; D024061:Collagen Type III / Q000097:blood*; D024141:Collagen Type IV / Q000097:blood; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology*; D006820:Hyaluronic Acid / Q000097:blood; D006909:Hydroxyproline / Q000378:metabolism*; D007797:Laminin / Q000097:blood; D008168:Lung / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008419:Materia Medica / Q000494:pharmacology; D010946:Plants, Medicinal / Q000737:chemistry; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D024061:Collagen Type III; D024141:Collagen Type IV; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D007797:Laminin; D008419:Materia Medica; D001761:Bleomycin; C025703:bleomycetin; D006820:Hyaluronic Acid; D006909:Hydroxyproline